BST2
Overview
BST2 (Bone Marrow Stromal Cell Antigen 2, also known as CD317 or tetherin) is a type II transmembrane protein with roles in innate immune defense and viral restriction. In cancer, BST2 has been identified as a potential immunomodulatory target based on differential DNA methylation and expression patterns in esophageal squamous cell carcinoma subtypes.
Alterations observed in the corpus
- BST2 shows lower DNA methylation and higher expression in the ESCC2 molecular subtype (P=3×10^-4, Fisher exact test) in the TCGA multi-platform esophageal carcinoma study; flagged as a potential immunomodulatory target PMID:28052061
Cancer types (linked)
- ESCC: Differential methylation and expression in ESCC2 subtype; BST2 inhibition proposed as a subtype-directed therapeutic strategy PMID:28052061
Co-occurrence and mutual exclusivity
- BST2 hypomethylation co-occurs with NOTCH/PI3K pathway alterations and immune infiltration in ESCC2 subtype PMID:28052061
Therapeutic relevance
- BST2-inhibition proposed as a potential therapeutic approach specifically in the ESCC2 (NOTCH/PI3K/immune-infiltrated) subtype; not yet tested clinically PMID:28052061
Open questions
- Whether BST2 hypomethylation and overexpression in ESCC2 is a driver event or a bystander of immune infiltration remains unresolved PMID:28052061
Sources
This page was processed by entity-page-writer on 2026-05-15.